Source comparison
Comparison: Subq vs IM vs Intranasal Peptide Administration
Subcutaneous (Subq) 15–30 minutes 85–95% 45° angle, 4–6mm into fatty tissue Low. Self-administered easily Optimal for ipamorelin; consistent absorption, minimal discomfort, simple technique Intramuscular (IM) 10–20 minutes 90–100% 90° angle, 1–1.5 inches into
This comparison does not assign a generated winner or score.
- Subcutaneous (Subq)
- 15–30 minutes
- 85–95%
- 45° angle, 4–6mm into fatty tissue
- Low. Self-administered easily
- Optimal for ipamorelin; consistent absorption, minimal discomfort, simple technique
- Intramuscular (IM)
- 10–20 minutes
- 90–100%
- 90° angle, 1–1.5 inches into muscle
- Moderate. Requires correct muscle identification
- Not recommended for ipamorelin; faster absorption offers no benefit, higher pain, risk of nerve/vessel damage
- Intranasal Spray
- 5–15 minutes
- 40–60%
- N/A. Mucosal absorption
- Very low. No injection required
- Convenient but inefficient; significant peptide loss via drainage and enzymatic degradation in nasal mucosa
- Subcutaneous administration is the standard for ipamorelin because it balances high bioavailability with technical simplicity. Intramuscular injection achieves marginally faster absorption but offers no therapeutic advantage for a peptide with a 2-hour half-life. The bioactivity window is identical. Intranasal delivery avoids needles but sacrifices more than half the dose to mucosal degradation, making it cost-ineffective for research applications where precise dosing matters.